Advanced stomach cancer has long been one of oncology’s hardest problems, a disease that is frequently caught late and that, once it has spread, offers patients grim survival odds. Results from a large international trial now point to meaningful progress. A newer targeted antibody, added to standard chemotherapy, reduced the risk of the cancer worsening or killing patients by 35 percent compared with the previous standard of care, and it pushed median survival more than seven months longer in a group of patients defined by a specific tumor marker.
A bispecific antibody aimed at HER2
The drug at the center of the trial is zanidatamab, an antibody engineered to latch onto two different spots on a protein called HER2, which sits on the surface of some cancer cells and drives their growth. Roughly one in five gastric and gastroesophageal tumors carries extra HER2, making it a well-established target. What distinguishes zanidatamab from earlier HER2 drugs is its dual-binding design, which lets it grip the protein more tightly and, in theory, disrupt the growth signal more effectively than a conventional single-site antibody.
The study, known as HERIZON-GEA-01, tested that idea in patients with HER2-positive, locally advanced or metastatic gastroesophageal adenocarcinoma who had not yet been treated for their advanced disease. As the published trial report describes, the design compared zanidatamab-based combinations against the older regimen built around trastuzumab, the HER2 antibody that has anchored treatment for more than a decade.
The numbers behind the 35 percent
The headline figure comes from how the trial measured disease control. Patients receiving the zanidatamab regimen saw their risk of the cancer progressing or causing death fall, reflected in a hazard ratio of 0.65 against the comparison group, which translates to a 35 percent reduction. Median progression-free survival, the length of time before the cancer worsened, stretched to 12.4 months versus 8.1 months with the older treatment.
Overall survival, the measure that matters most to patients, moved as well. When zanidatamab was combined with the immunotherapy tislelizumab and chemotherapy, median overall survival reached 26.4 months, compared with 19.2 months for trastuzumab plus chemotherapy. As the company behind the drug reported, that gap of more than seven months represents one of the larger survival extensions seen in this setting in years.
Why a seven-month gain carries weight here
Numbers like these land differently depending on the disease. In a cancer with a decent prognosis, an extra several months might register as incremental. In advanced gastric cancer, where median survival has historically hovered around a year to a year and a half, extending the typical patient’s life to well beyond two years is a substantial shift. The disease is often diagnosed at a late stage because early stomach cancer produces vague symptoms, so most patients enter treatment already facing metastatic disease and limited options.
The trial also reinforces a broader lesson in cancer care: matching the drug to the tumor’s biology pays off. By enrolling only patients whose tumors overexpress HER2, the study concentrated the treatment where it was most likely to work, an approach that has repeatedly outperformed one-size-fits-all chemotherapy across many cancer types.
Chemotherapy, antibody and immunotherapy together
Part of what makes the result notable is the combination itself. The strongest survival benefit came from stacking three mechanisms at once: chemotherapy to kill dividing cells, the HER2-targeted antibody to choke off a growth signal, and an immunotherapy that helps the immune system recognize the tumor. Each attacks the cancer differently, and the trial’s design let researchers see how the additions built on one another. Commentary from oncologists reviewing the data described the survival gains as a meaningful advance for a patient population that has seen few.
Layering therapies this way is a recurring strategy in modern oncology, and it comes with a tradeoff. More active drugs can mean more side effects, so the balance between benefit and toxicity is central to whether a regimen becomes a practical standard rather than merely an effective one on paper.
What still has to happen before it reaches clinics widely
A strong trial result is a milestone, not the finish line. Survival benefits must be weighed against the burden of treatment, including how patients tolerate a three-drug combination over many months, and regulators review the full safety picture before a regimen becomes broadly available. The findings position zanidatamab-based treatment as a leading candidate to reshape the first-line approach to HER2-positive disease, but the pace of adoption will hinge on regulatory decisions and real-world experience.
The trajectory nonetheless fits a hopeful pattern. Stomach cancer treatment moved slowly for years, leaning on chemotherapy with modest additions. A trial that improves both how long patients hold their disease at bay and how long they live, in a clearly defined biological subgroup, is the kind of result that tends to redraw treatment guidelines rather than simply add a footnote to them.
This article was produced with the assistance of AI and reviewed by the Morning Overview editorial team.
More from Morning Overview
- The NSA is again telling phone owners to switch off one location setting
- A handful of car transmissions are so tough mechanics say they almost never fail
- A handful of SUVs keep hitting 300,000 miles, and they share one engine trait
- Supplements now rank as the fifth-leading cause of death from liver disease.
